Failure of Lactobacillus spp. to prevent bacterial translocation in a rat model of experimental cirrhosis

J Hepatol. 2002 Apr;36(4):501-6. doi: 10.1016/s0168-8278(02)00003-x.

Abstract

Background/aims: Prophylaxis of spontaneous bacterial peritonitis in cirrhotic patients with norfloxacin is associated with emergence of quinolone-resistant Enterobacteriaceae. We investigated whether an alternative strategy with Lactobacillus prevents bacterial translocation and ascitic fluid infection in cirrhotic rats.

Methods: CCl(4)-induced cirrhotic rats with ascites (n=34) were allocated to treatment with oral Lactobacillus strain GG at 1-2 x 10(9) cfu/day for 8-10 days (group LGG) or milk (group MILK). In addition, 20 cirrhotic rats were given a single dose of 15 mg norfloxacin orally and then allocated to Lactobacillus (group NOR-LGG) or milk (group NOR-MILK). Ten healthy rats served as control. After sacrifice the cecal flora were analyzed and the prevalence of bacterial translocation and ascitic fluid infection assessed.

Results: Cecal colonization with Lactobacillus was achieved in 90% of treated rats. The prevalence of bacterial translocation to mesenteric lymph nodes was 10% in control rats and 93, 84, 70 and 100% in groups MILK, LGG, NOR-MILK and NOR-LGG, respectively (P>0.1 for comparison of treatment groups), the prevalence of ascitic fluid infection was 60, 32, 40 and 40% (P>0.1). Bacterial translocation of Lactobacillus was observed in 24% of rats treated.

Conclusion: Lactobacilli fail to prevent bacterial translocation and ascitic fluid infection in experimental cirrhosis in spite of successful intestinal colonization.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology
  • Ascitic Fluid / microbiology
  • Bacteria / isolation & purification
  • Bacterial Infections / epidemiology
  • Bacterial Translocation / drug effects
  • Bacterial Translocation / physiology*
  • Cecum / microbiology
  • Colony Count, Microbial
  • Enterobacteriaceae / physiology
  • Lactobacillus / physiology*
  • Liver Cirrhosis / microbiology*
  • Male
  • Norfloxacin / pharmacology
  • Prevalence
  • Probiotics / therapeutic use*
  • Rats
  • Rats, Wistar

Substances

  • Anti-Bacterial Agents
  • Norfloxacin